Bo M, Bonino F, Neirotti M, Gottero M, Pernigotti L, Molaschi M, Fabris F
Institute of Gerontology, University of Turin, Italy.
Angiology. 1991 Feb;42(2):106-13. doi: 10.1177/000331979104200204.
The effects on the coagulative and rheologic pattern of two lipid-lowering drugs, bezafibrate and simvastatin, were studied in 36 hypercholesterolemic subjects. Patients were randomly divided into two groups (18 subjects each) and received bezafibrate R 400 mg/day or simvatatin 10-40 mg/day over a twelve week period. Besides a decrease in plasma fibrinogen and fibrinopeptide A (p less than 0.001 both), bezafibrate induced a reduction of factor VIIc and VIIIc activity (p less than 0.001 both), while antithrombin 3 activity was increased (p less than 0.001) and the hemorheologic pattern was greatly improved (p less than 0.001). Simvastatin caused a slight decrease in factor VIIIc activity and a moderate reduction of beta-thromboglobulin. The efficacy of bezafibrate in reducing the activation of the coagulative cascade and improving the hemorheologic pattern has been confirmed; the peculiar triglycerides- and fibrinogen-lowering effect of the drug, not observed with simvastatin, could be responsible for these modifications.
在36名高胆固醇血症患者中研究了两种降脂药物——苯扎贝特和辛伐他汀对凝血和流变学模式的影响。患者被随机分为两组（每组18名），并在12周内接受每天400毫克苯扎贝特或每天10 - 40毫克辛伐他汀的治疗。除了血浆纤维蛋白原和纤维蛋白肽A减少（两者p均小于0.001）外，苯扎贝特还导致因子VIIc和VIIIc活性降低（两者p均小于0.001），而抗凝血酶3活性增加（p小于0.001），血液流变学模式得到显著改善（p小于0.001）。辛伐他汀导致因子VIIIc活性略有下降，β-血小板球蛋白中度降低。苯扎贝特在降低凝血级联激活和改善血液流变学模式方面的疗效已得到证实；该药物独特的降低甘油三酯和纤维蛋白原的作用，辛伐他汀未观察到，可能是这些改变的原因。
